Abstract
RNA interference (RNAi) is a naturally occurring regulatory process that controls posttranscriptional gene expression. Small interfering RNA (siRNA), a common form of RNAi-based therapeutics, offers new opportunities for cancer therapy via silencing specific genes, which are associated to cancer progress. However, clinical applications of RNAi-based therapy are still limited due to the easy degradation of siRNA during body circulation and the difficulty in the delivery of siRNA to desired tissues and cells. Thus, there have been many efforts to develop efficient siRNA delivery systems, which protect siRNA from serum nucleases and deliver siRNA to the intracellular region of target cells. Here, the recent advances in siRNA nanocarriers, which possess tumor-targeting ability are reviewed; various nanoparticle systems and their antitumor effects are summarized. The development of multifunctional nanocarriers for theranostics or combinatorial therapy is also discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1182-1193 |
| Number of pages | 12 |
| Journal | Advanced healthcare materials |
| Volume | 3 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Biomedical Engineering
- Biomaterials
- Pharmaceutical Science
Cite this
Tumor-targeting multifunctional nanoparticles for sirna delivery : Recent advances in cancer therapy. / Ku, Sook Hee; Kim, Kwang Meyung; Choi, Kuiwon; Kim, Sun Hwa; Kwon, Ick Chan.
In: Advanced healthcare materials, Vol. 3, No. 8, 01.01.2014, p. 1182-1193.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor-targeting multifunctional nanoparticles for sirna delivery
T2 - Recent advances in cancer therapy
AU - Ku, Sook Hee
AU - Kim, Kwang Meyung
AU - Choi, Kuiwon
AU - Kim, Sun Hwa
AU - Kwon, Ick Chan
PY - 2014/1/1
Y1 - 2014/1/1
N2 - RNA interference (RNAi) is a naturally occurring regulatory process that controls posttranscriptional gene expression. Small interfering RNA (siRNA), a common form of RNAi-based therapeutics, offers new opportunities for cancer therapy via silencing specific genes, which are associated to cancer progress. However, clinical applications of RNAi-based therapy are still limited due to the easy degradation of siRNA during body circulation and the difficulty in the delivery of siRNA to desired tissues and cells. Thus, there have been many efforts to develop efficient siRNA delivery systems, which protect siRNA from serum nucleases and deliver siRNA to the intracellular region of target cells. Here, the recent advances in siRNA nanocarriers, which possess tumor-targeting ability are reviewed; various nanoparticle systems and their antitumor effects are summarized. The development of multifunctional nanocarriers for theranostics or combinatorial therapy is also discussed.
AB - RNA interference (RNAi) is a naturally occurring regulatory process that controls posttranscriptional gene expression. Small interfering RNA (siRNA), a common form of RNAi-based therapeutics, offers new opportunities for cancer therapy via silencing specific genes, which are associated to cancer progress. However, clinical applications of RNAi-based therapy are still limited due to the easy degradation of siRNA during body circulation and the difficulty in the delivery of siRNA to desired tissues and cells. Thus, there have been many efforts to develop efficient siRNA delivery systems, which protect siRNA from serum nucleases and deliver siRNA to the intracellular region of target cells. Here, the recent advances in siRNA nanocarriers, which possess tumor-targeting ability are reviewed; various nanoparticle systems and their antitumor effects are summarized. The development of multifunctional nanocarriers for theranostics or combinatorial therapy is also discussed.
KW - Cancer therapy
KW - Multifunctional nanoparticles
KW - SiRNA delivery
KW - Tumor targeting
UR - http://www.scopus.com/inward/record.url?scp=84906077659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906077659&partnerID=8YFLogxK
U2 - 10.1002/adhm.201300607
DO - 10.1002/adhm.201300607
M3 - Article
C2 - 24577795
AN - SCOPUS:84906077659
VL - 3
SP - 1182
EP - 1193
JO - Advanced healthcare materials
JF - Advanced healthcare materials
SN - 2192-2640
IS - 8
ER -